The clinical safety, biodistribution and internal radiation dosimetry of [18F]AH113804 in healthy adult volunteers by E. J. Somer et al.
ORIGINAL RESEARCH Open Access
The clinical safety, biodistribution and
internal radiation dosimetry of
[18F]AH113804 in healthy adult volunteers
E. J. Somer1*, R. Owenius4,2, A. Wall2, G. Antoni3, A. Thibblin3 and J. Sörensen2
Abstract
Background: Quantitative biodistribution, venous blood and excretion data have been obtained following the
intravenous bolus injection of AH113804 (18F) Injection in six healthy volunteers (HVs), four males and two females,
up to approximately 5 h post-injection.
For each subject, key organs and tissues were delineated and analytical fits were made to the image data as
functions of time to yield the normalised cumulated activities. These were input to an internal radiation dosimetry
calculation based upon the Medical Internal Radiation Dose (MIRD) schema for the Cristy-Eckerman adult male or
female phantom. The absorbed doses per unit administered activity to the 24 MIRD-specified target organs were
evaluated for an assumed 3.5-h urinary bladder voiding interval using the Organ Level INternal Dose Assessment/
Exponential Modelling (OLINDA/EXM) code. The sex-specific absorbed doses were then averaged, and the effective
dose per unit administered activity was calculated.
Results: Excluding the remaining tissue category, the three source regions with the highest mean initial 18F activity
uptake were the liver (18.3%), lung (5.1%) and kidney (4.5%) and the highest mean normalised cumulated activities
were the urinary bladder contents and voided urine (1.057 MBq h/MBq), liver (0.129 MBq h/MBq) and kidneys (0.
065 MBq h/MBq). The three organs/tissues with the highest mean sex-averaged absorbed doses per unit
administered activity were the urinary bladder wall (0.351 mGy/MBq), kidneys (0.052 mGy/MBq) and uterus (0.
031 mGy/MBq).
Conclusions: AH113804 (18F) Injection was safe and well tolerated. Although the effective dose, 0.0298 mSv/MBq, is
slightly greater than for other common 18F PET imaging radiopharmaceuticals, the biodistribution and radiation
dosimetry profile remain favourable for clinical PET imaging.
Background
The tyrosine-kinase receptor c-Met (also known as MET)
and its ligand, the hepatocyte growth factor (HGF), have
been shown to be involved in tumour growth, invasion
and metastasis in many human cancers of epithelial origin
[1]. This makes c-Met a potential target for molecular im-
aging diagnostics and therapy.
A recent in vivo study to visualise c-Met expression
was carried out using the engineered anticalin molecule
PRS 110, with monovalent specificity for c-Met, radiola-
belled with 89Zr to asses specific uptake in different hu-
man tumour xenograft models [2]. This study showed a
dose-dependent specific tumour uptake of [89Zr]PRS-
110 in the c-Met-expressing H441 (non-small cell lung
cancer) and U87-MG (primary glioblastoma) tumours,
whereas the uptake was lower (similar to non-specific
control uptake) in the c-Met-negative A270 (ovarian
cancer) tumour model.
AH113804 (18F) Injection is an investigational, c-Met-
targeted positron emission tomography (PET) imaging
agent under development for the detection and quantifica-
tion of c-Met expression. The [18F]AH113804 molecule
consists of a 26-amino acid cyclic peptide (AH111972)
that is conjugated with 4-[18F]fluorobenzaldehyde (Fig. 1).
The synthesis of [18F]AH113804 has been described
by Arulappu et al., together with an in vivo analysis
of the utility of [18F]AH113804 for the detection of
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loco-regional recurrence of basal-like breast cancer in
a mouse model [3].
A fluorescent cyanine-dye-labelled version of
AH111972 (GE-137) has also been evaluated in a clinical
phase 1 study in 20 healthy volunteers and 15 subjects
with high risk of colorectal cancer [4]. In preparation of
that study, GE-137 was shown to bind with high affinity
to human c-Met with a dissociation constant, Kd, of 3.0
± 0.5 nM in a fluorescence polarisation binding assay
and 2.7 ± 1.5 nM in a cell-based ligand binding assay
with MKN45 cells that highly express human c-Met.
In addition, conjugation with 4-fluorobenzaldehyde
(AH113804) was found to have no relevant effect on the
binding of AH111972 to human c-Met (Ki of unlabelled
AH113804 was not significantly different to that of
AH111972 tested against GE-137 in a fluorescence po-
larisation competition assay; data not shown).
The intended use of AH113804 (18F) Injection is for
PET imaging of c-Met expression in cancerous lesions
with a potential objective to provide guidance in the se-
lection of therapy and motivate the inclusion of c-Met
inhibitors with the current standard therapy for add-
itional benefit to the patient. PET imaging with the 18F-
labelled glucose analogue fluorodeoxyglucose ([18F]FDG)
was recently used to monitor the treatment response of
crizotinib, a c-Met inhibitor designed to induce apop-
tosis, in mice with solid tumours [5]. However, in line
with the conclusion of Newbold and co-workers, it
would be advantageous to use a direct PET measure of
apoptosis or c-Met expression in the monitoring of
response to such drugs in addition to the metabolic as-
sessment provided by [18F]FDG.
The objectives of this work were to assess the safety of
a single dose of AH113804 (18F) Injection in healthy vol-
unteers, to determine the biodistribution of 18F following
intravenous (iv) administration of AH113804 (18F) Injec-
tion and to calculate the internal radiation dosimetry
and the effective dose in healthy volunteers.
Methods
Unless otherwise stated, all numerical data are provided
as the mean ± 1 standard deviation.
Radiopharmaceutical preparation
The target compound [18F]AH113804 was prepared in a
two-step route starting with synthesis and purification of
4-[18F]fluorobenzaldehyde from 4-(trimethylammonium)-
benzaldehyde triflate, followed by the reaction of the la-
belled aldehyde with the deprotected peptide precursor
(Fig. 1).
[18F]Fluoride anion was produced via the 18O(p,n)18F
nuclear reaction using a Scanditronix MC17 cyclotron.
The bombardment of enriched 18O water (98%, Rotem)
gave an aqueous solution of 18F− which was transferred
from the cyclotron target using helium. The 18F− (30–
50 GBq) was trapped on a QMA column and eluted with
kryptofix K222 and aqueous potassium hydrogen carbon-
ate in acetonitrile (5.1 mg K222, 320 μL MeCN, 1.4 mg
KHCO3, 80 μL water). This mixture was dried at 105–
120 °C for 9.2 min. The aldehyde precursor (3.8 mg)
Fig. 1 Synthesis scheme of [18F]AH113804
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dissolved in 2 mL of dry DMSO was added to the dried
18F− kryptofix complex. The reaction mixture was heated
at 80 °C for 2 min. 4-[18F]Fluorobenzaldehyde was puri-
fied with an Oasis MCX plus extraction cartridge using
4 mL of 4% aqueous ammonia and eluted in 1 mL of
ethanol.
Five-milligramme peptide in 2.2 mL of aniline hydro-
chloride (10 mg/mL) was added to the purified labelled
aldehyde. After 6.9 min at 60 °C, the crude product was
diluted with sterile water and purified on a preparative
HPLC column (Waters Xbridge Shield, 5 μm, 10 ×
100 mm column with MeCN in 50 mM ammonium
acetate, flow 4 mL/min; 0–1 min 15% MeCN, 1–16 min
gradient 15–40% MeCN, 16–20 min gradient 40–100%
MeCN) connected to a Knauer UV detector and a
Bioscan RAD detector. Radiosynthesis was carried out
on a FASTlab synthesiser module (GE Healthcare) using
a single-use disposable AH113804 (18F) Injection FAS-
Tlab cassette. The product was formulated in 21 mL
of phosphate-buffered saline containing sodium p-
aminobenzoate (2.38 mg/mL). Sterile filtration was
done on a Fluorodyne® 25-mm syringe filter (0.2 μm) (Pall
Corporation, USA). The activity of the product was ap-
proximately 250 MBq/mL. The tracer production, includ-
ing the drying of the [18F]fluoride anion and formulation
of the purified product, took about 1 h.
The product identification and purity check was done
by analytical reversed-phase HPLC utilizing a Phenom-
enex Kinetex C18, 2.6 μm, 100 × 4.6 mm column
equipped with a Security Guard Ultra C18 cartridge with
10 mM ammonium acetate buffer (A) and methanol/
acetonitrile 70:30 (v/v) (B). The gradient method was as
follows: 0–3 min 30% B, 3–5 min 30–40% B, 5–32 min
40% B.
Subjects
Six healthy volunteers (four men and two women) were
enrolled. The age, whole body weight and body mass
index (BMI) were 22 ± 2 years, 84 ± 10 kg and 27 ± 4 kg/
m2, respectively (Table 1). The subject inclusion criteria
included age greater than 18 years, the ability to provide
informed written consent, normal medical history,
physical examination and vital-sign findings, and a BMI
between 18 and 30 kg/m2. The subject exclusion criteria
included pregnancy and current lactation.
Administration
AH113804 (18F) Injection was administered intraven-
ously as a slow (approximately 0.5–1 mL/s) bolus injec-
tion followed by a 10-mL saline flush. The mean
administered activity was 141.5 ± 6.7 MBq with a mean
injected volume of 1.8 ± 0.4 mL.
Safety data
Safety data were collected up to 24 h after injection and
included adverse events (AEs), vital signs (blood pres-
sure, respiratory rate, heart rate and body temperature),
physical examination (lungs, cardiovascular system and
abdomen), electrocardiogram, laboratory parameters
(serum biochemistry, haematology, coagulation parame-
ters and urinalysis) and injection site status. Two-
millilitre venous blood samples were collected through
an indwelling catheter at a nominal 2-, 5-, 10-, 15-, 30-,
60-, 90-, 180- and 260-min post-injection, and 18F activ-
ity concentration in a single sample of whole blood and
plasma was determined in a well counter (in-house de-
sign including 3MW3/3 detector, Saint-Gobain Crystals)
that was cross-calibrated against the scanner and subject
to daily quality control.
Image acquisition and reconstruction
Emission images were acquired in 3D mode on a GE
Discovery ST PET/CT scanner with a 15.7-cm axial field
of view (FOV). A whole-body CT image was acquired
for attenuation correction prior to the administration of
AH113804 (18F) Injection. The axial extent of the ac-
quired emission images was from the crown of the head
to approximately mid-thigh so as to ensure that the
urinary bladder was included in the image. Hence, a
whole-body emission scan consisted of contiguous static
positions acquired at a variable number of bed positions,
depending on the subject’s height. Any 18F activity out-
side the FOV was assumed to be uniformly distributed
throughout the unimaged anatomy.
Table 1 Subject demographics and administered activity. Body mass index = weight[kg]/height[m]2
Subject Sex Age (year) Weight (kg) Height (cm) Body mass index (kg/m2) Administered activity (MBq)
1 Male 21 68.5 182 21 140
2 Female 21 91.2 177 29 143
3 Male 21 78.6 175 26 137
4 Male 26 79.9 184 24 135
5 Male 21 95.0 179 30 140
6 Female 23 92.0 174 30 154
Mean – 22 84.2 178 27 142
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Eight serial 3D whole-body PET images were ac-
quired for each subject beginning nominally at 2 min
and ending up to 6 h post-injection (p.i.). In order to
compensate for the physical decay of 18F activity during
imaging, the acquisition time for each bed position was
increased from 30 to 60 s at 26 min and to 120 s at
220 min p.i. Images were acquired in three separate
sessions between which the subjects were allowed to
leave the scanner bed. Prior to the second and third
emission imaging sessions, additional whole-body CT
attenuation correction scans were performed. Correc-
tions for scatter events and random coincidences were
performed as per the models provided by the scanner’s
manufacturer.
Subjects were encouraged to void and were given a
yoghurt drink between imaging sessions to prompt gall-
bladder drainage into the duodenum. All urinary voids
were collected and the volumes and 18F activity concen-
trations measured.
Emission images were reconstructed with both or-
dered subset expectation maximisation (OSEM) with 2
iterations and 21 subsets with post-reconstruction
smoothing using an isotropic Gaussian filter (4.29 mm
full-width at half-maximum) and filtered back-projection
(FBP). Slice thickness was 3.27 mm with a pixel size of
3.91 mm in the OSEM reconstruction and 5.47 mm in
the FBP.
Quantification of activity
Image analysis was performed on a MIM workstation
(version 6.0, MIM Software Inc., Cleveland) which in-
cludes a tool for volume of interest (VOI) definition
using a predefined VOI template and an image regis-
tration algorithm. A set of VOIs were initially drawn
around organs that could be readily delineated on the
CT component of the PET/CT scan. These organs in-
cluded the brain, salivary glands, thyroid, lungs, heart,
liver, spleen and kidneys. The defined VOIs were reg-
istered to a common CT template using a non-rigid
deformation algorithm and stored in the MIM data-
base. This database was augmented as delineation was
performed on successive subjects.
Analysis regions were defined using the templatized
VOI database and were then manually edited using the
fused CT and OSEM PET images as a guide. Having de-
fined a VOI set for imaging session 1, these were trans-
lated as required and applied to sessions 2 and 3. Finally,
VOIs were applied to the FBP data and the resulting
mean activity concentration (Bq/mL) per region, the re-
gion volume (mL) and the standard deviation of counts
within each region at each time point were exported in
spreadsheet format. It was assumed that organs did not
change in size or shape during the course of the
acquisition with the notable exceptions of the bladder
and the intestinal contents.
As the contents of the small intestine varied with
time, VOIs were drawn on each time frame, and
where no significant uptake could be identified, the
VOI from the nearest available time point was copied
to provide a measure of background activity. Back-
ground activity was included in the fitted model and
subtracted from the resulting calculation of normal-
ised cumulated activity and injected fraction entering
the small intestine.
The activity within the cardiac chambers was esti-
mated from the product of the measured whole blood
activity and the chamber volume (477 mL for males,
351 mL for females representing 9% of the total blood
volume) [6]. The activity within the cardiac wall was
then estimated by subtracting the activity within the car-
diac chambers from the activity within a whole heart
VOI.
The presence of significant artefacts in the region of
the bladder on both the FBP and OSEM reconstructed
images complicated the analysis and bladder activity was
estimated in two ways.
The first method used a 42% maximum intensity
threshold VOI drawn on each time frame. The second
method assumed the bladder was the only significant
source within a rectangular VOI positioned to include
the whole FOV over the maximum axial extent of the
bladder. This whole-slice VOI was not resized as the
bladder filled to ensure that the background component
of the measured activity was as constant as possible. The
change in background activity with time as a conse-
quence of biological clearance was considered insignifi-
cant compared to the change in bladder activity per se.
This background activity was then accounted for by in-
cluding a constant term in the model used for curve
fitting.
Administered activity not accounted for by the defined
VOIs or excretion was assigned to the remainder
category.
Measured activity data for each source region, rs, were
decay-corrected to the time of injection and normalised
to the administered activity. These data were then fitted
to the generalised analytical function of Eq. 1,




−λrS ;i t ð1Þ
where αrS;i and λrS;i are parameters extracted from a
Simplex (GRG Nonlinear Solver, Microsoft Excel) fit
minimising the weighted sum of squared difference
between the model and the biodistribution data. The
constant term, CrS , was either fixed to zero or fitted
alongside the other parameters. Mono- (N = 1) and bi-
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exponential (N = 2) fits were performed with and with-
out the inclusion of the constant background term.
The selection of the appropriate equation to fit to the
data was made using the Akaike Information Criterion
(AIC) [7]. Fitted functions were subsequently integrated,
after first accounting for the effect of 18F physical decay,
to yield the normalised cumulative activities (NCAs) of
the VOI [8]. The NCA of the urinary bladder contents
and voided urine was calculated from the analytical fit to
the summed activities in the urinary bladder contents
and voided urine using a dynamic urinary bladder model
[9]. As recommended by the International Commission
on Radiological Protection (ICRP), a 3.5-h voiding inter-
val was assumed [10].
Internal radiation dosimetry
The internal radiation dosimetry for each subject was
determined following the Medical Internal Radiation
Dose (MIRD) schema [11]. For each subject, the
NCAs were used as input to the Organ Level Internal
Dose Assessment/Exponential Modelling (OLINDA/
EXM) software [12] to calculate the absorbed doses
to the 24 MIRD-specified target regions of the Cristy-
Eckerman adult hermaphrodite male and adult female
phantoms [13].
Following the recommendations of Publication 103 of
the ICRP [14], these absorbed doses were then sex-
averaged and the effective dose was evaluated using the
tissue weighting factors of Publication 60 of the ICRP
[15]. Recommendations of the ICRP subsequent to this
publication were followed in the effective dose evalu-
ation: the absorbed dose to the thymus gland was used
as a surrogate for that to the oesophagus; the absorbed
dose to the colon wall was calculated as the mass-
weighted sum of the absorbed doses to the walls of the
upper and lower large intestines; and the gonadal
absorbed dose was taken to be the mean of the absorbed
doses to the testes and ovaries [16].
Results
Unless otherwise stated, all 18F activities are decay-
corrected to the time of injection and expressed as a
percentage of the administered activity.
Safety
No AEs were reported and no clinically significant
trends were noted for any safety parameter after admin-
istration as summarised below.
1) No deaths, serious AEs or clinically significant
AEs were reported during the study. No study-
emergent AEs were reported for any subject
during the study.
2) No clinically significant changes in mean values of
haematology, biochemistry, coagulation or urinalysis
parameters were evident. In addition, no clinically
significant shifts in individual laboratory values for
healthy volunteers were noted.
Fig. 2 Representative PET Maximum Intensity Projections (MIP) following administration of AH113804 (18F) Injection. Representative OSEM PET
Maximum Intensity Projection (MIP) of a subject 4 and b subject 2 following administration of AH113804 (18F) Injection. Acquisitions shown were
performed at approximately (left to right) 0, 0.2, 0.5, 1.0, 2.5 and 3.7 h p.i. and features of note include the injection site on the left arm, the initial
uptake in the heart and liver, clearance through the kidneys and the appearance of the gallbladder in later time frames. In subject 2, artefacts
around the bladder are also apparent where the bladder activity is greatest
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3) No ECG abnormalities (changes) or trend indicative
of an adverse safety signal were noted.
4) No clinically significant changes in vital signs
parameters in healthy volunteers were noted.
Biodistribution
Figure 2 shows examples of PET images in male and fe-
male subjects over the course of the study following the
administration of AH113804 (18F) Injection.
Excluding the remaining tissue category, the three
source regions with the highest mean initial 18F activ-
ity uptake (defined as that at the initial imaging time
point which was nominally 2 min p.i.) were the liver
at 18.3 ± 2.9% (range 15.6–23.8%), the lung at 5.1 ±
0.8% (range 3.9–5.9%) and the kidney at 4.5 ± 0.5%
(range 3.8–5.1%). Initial uptake in the brain, gallblad-
der, salivary glands, thyroid and cardiac wall was less
than 1% of the injected activity in each of these or-
gans/tissues.
Fig. 3 Time-activity curves for organs exhibiting the greatest uptake. Mean time-activity curves for the liver, lung and kidney being the organs
with the highest initial uptake. Activity is corrected for physical decay and normalised to the injected dose. Error bars represent the range of the
data and points have been offset slightly on the x-axis for clarity
Fig. 4 Time-activity curves for the urinary bladder illustrating the activity underestimation of the threshold VOI. Mean time-activity curves for the
urinary bladder plus the measured voided activity determined from the 42% threshold VOI and the whole slice method. Error bars indicate the
range of the data, and data has been offset slightly on the x-axis for clarity. The broken lines show the results of fitting the function A(t) = C + α e− λt
(see Eq. 1). In the case of the whole slice region (C = 88, α = −88 and λ = 0.3131), the percentage of activity excreted through the renal pathway is
88%, and for the threshold VOI (C = 266, α = −266 and λ = 0.0598), the fitted parameters are not physiologically meaningful (i.e. renal
excretion of 266%)
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Washout of 18F activity from the liver was generally
rapid, falling to approximately 30% of its initial value at
1 h p.i. and less than to 10% of the initial value at 4 h
p.i. Similarly, washout of 18F activity from the lungs was
also rapid, reaching approximately 50% of its initial value
at 1 h p.i. and 20% at 4 h p.i. The mean time-activity
curves for the liver, lung and kidney for all subjects are
shown in Fig. 3.
There was rapid clearance and excretion of 18F activity,
primarily through the renal pathway, with about 60% ex-
creted within 4 h after injection. Figure 4 illustrates the
difference between the two methods used to evaluate the
activity of the bladder contents plus voids. An attempt
to model the data from the subject averaged data from
the threshold VOI suggests an impossible total renal ex-
cretion of 266% of the injected activity. The whole-slice
Fig. 5 Normalised whole blood and plasma time-activity curves. Normalised whole blood and plasma time-activity curves for the five subjects
where blood sampling was possible. The error bars indicate the range of the data and have been offset slightly for clarity
Table 2 Normalised cumulative activity (NCA) for organs and tissues of significant uptake







001–0011 001–0012 001–0013 001–0014 001–0015 001–0016
Sex M F M M M F M F
Brain 1.02E−02 8.37E−03 1.02E−02 1.05E−02 8.29E−03 7.26E−03 9.78E−03 7.81E−03
Gallbladder 2.19E−03 5.74E−04 2.20E−03 2.84E−03 1.71E−03 5.53E−04 2.23E−03 5.64E−04
Heart contents 2.87E−02 2.27E−02 3.41E−02 3.10E−02 2.78E−02 2.53E−02 3.04E−02 2.40E−02
Heart wall 8.38E−03 1.67E−02 4.11E−03 6.37E−03 2.67E−03 1.37E−02 5.38E−03 1.52E−02
Kidneys 4.13E−02 1.28E−01 4.92E−02 5.04E−02 5.97E−02 6.24E−02 5.02E−02 9.52E−02
Liver 1.29E−01 1.27E−01 1.74E−01 1.24E−01 1.09E−01 1.11E−01 1.34E−01 1.19E−01
Lungs 5.99E−02 3.95E−02 5.05E−02 6.16E−02 5.62E−02 5.25E−02 5.71E−02 4.60E−02
Intestinal contents Small intestine 2.20E−03 0.00E+00 6.35E−04 0.00E+00 3.73E−03 2.70E−03 1.64E−03 1.35E−03
Bolus (unitless) 3.53E−03 0.00E+00 1.07E−03 0.00E+00 6.95E−03 5.38E−03 2.89E−03 2.69E−03
Spleen 1.78E−02 1.62E−02 1.66E−02 1.38E−02 2.00E−02 1.43E−02 1.71E−02 1.52E−02
Thyroid 6.61E−04 5.35E−04 9.35E−04 1.07E−03 6.17E−04 8.55E−04 8.20E−04 6.95E−04
Urinary bladder
contents
Fit 1.14E+00 1.09E+00 8.87E−01 9.13E−01 1.14E+00 1.15E+00 1.02E+00 1.12E+00
Dynamic model
(3.5-h voiding interval)
5.94E−01 6.15E−01 5.00E−01 5.29E−01 6.41E−01 6.52E−01 5.66E−01 6.34E−01
Remaining tissues 1.20E+00 1.23E+00 1.32E+00 1.43E+00 1.25E+00 1.12E+00 1.30E+00 1.17E+00
The ‘Bolus’ value for the intestinal contents is the maximum decay-corrected fraction of injected activity encompassed by the intestinal VOI and is input to the
ICRP 30 model within the OLINDA/EXM software
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method yields more reasonable results, with total renal
excretion of 88%.
The 18F activity concentration in whole blood was
characterised by bi-exponential decay with a 65% redis-
tribution component (T½ = 6 min) as blood and tissue
equilibrate and a 35% washout component (T½ = 2.1 h).
In plasma the redistribution component was 63%
(T½ = 6 min) and the washout component was 37%
(T½ = 1.7 h). The slightly slower washout of activity
from whole blood meant the ratio of whole blood activity
to plasma activity rose from an initial value of 0.6 to 0.75
at 4.4 h p.i. The mean washout of activity from whole
blood and plasma is shown in Fig. 5.
Blood sampling could not be carried out for subject 6
due to a malfunctioning sampling cannula, so instead, a
weighted average of the other five subjects data was used
as approximated blood and plasma curves [17]. The
negative implications from this approximation were
assessed as minor since data were only used in the esti-
mation of the dose to the heart.
Table 2 summarises the NCA values determined in
this study. If the remaining tissues category is ex-
cluded, the three source regions with the highest
mean normalised cumulated activities were the urin-
ary bladder (assuming 3.5 h void interval) with 0.589
± 0.062 MBq h/MBq (range 0.500–0.652), the liver
with 0.129 ± 0.024 MBq h/MBq (range 0.109–0.174)
and the kidneys with 0.065 ± 0.032 MBq h/MBq
(range 0.041–0.128).
The relatively high standard deviation in kidney
NCA can be attributed to subject 2. In this female
subject, tracer accumulated in the right kidney from
approximately 60 min p.i. until the subject voided at
the end of the first scan session (approximately
100 min p.i.). The bladder and kidney curves for this
subject are presented in Fig. 6. This accounts for the
high NCA in this subject’s kidney of 0.128 MBq h/
MBq compared to the mean of the remaining subjects
of 0.053 MBq h/MBq. As this represents a normal
variant, no attempt was made to correct or exclude
these data.
Internal radiation dosimetry
The absorbed doses per unit administered activity to
the MIRD-specified organs are provided in Table 3.
The three organs/tissues with the highest mean sex-
averaged absorbed doses per unit administered activity
were the urinary bladder wall (0.351 ± 0.083 mGy/
MBq), kidneys (0.052 ± 0.022 mGy/MBq) and uterus
(0.031 ± 0.000 mGy/MBq).
The sex-averaged effective dose per unit administered
activity was evaluated and was determined to be
0.0298 mSv/MBq (Table 4).
Discussion
This was a phase 1, single-centre, open-label study to evalu-
ate the clinical safety, biodistribution of 18F and the internal
radiation dosimetry associated with [18F]AH113804 in
healthy adult volunteers. The radiopharmaceutical was
found to be safe and well tolerated.
Methodology
In this study the biodistribution was evaluated from
PET/CT images of four male and two female subjects at
up to 16 time points up to 4.5 h p.i. and the dosimetry
evaluated using the OLINDA/EXM code.
High tracer concentration in the bladder, resulting
from rapid renal excretion, caused significant artefacts
in both FBP and OSEM reconstructed images. These
took the characteristic form of radial streaks in FBP
images or cold regions adjacent to the hot bladder in
OSEM reconstructions. The assumptions that, despite
these artefacts, the total number of counts recorded
within each slice remains accurate and that changes
in recorded activity are primarily due to the filling
and emptying of the bladder while the background
Fig. 6 Time-activity curves to illustrate the delayed drainage of urine
from the kidney to bladder in subject 2. Mean time-activity curves
for the bladder and kidney for all subjects, except for subject 2, are
presented with error bars to show the range of the data. Subject 2’s
curves are also presented for comparison. The shape of the kidney
curve in subject 2 is clearly abnormal and accounts for the high
calculated NCA. The same subject’s bladder curve exhibits a
corresponding reduction
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remains relatively constant, appear to hold true.
These artefacts may be the result of a failure of the
scatter correction algorithm in high count regions.
Acquisition in 2D mode may have limited scatter thus
reducing the appearance of these artefacts, but the
consequent loss of scanner sensitivity may have led to
longer acquisition times forcing data collection at
fewer time points. Phantom experiments are required
to confirm these assumptions.
Biodistribution
The rapid clearance of tracer from blood and back-
ground tissue suggests that, having established the
optimum imaging time p.i., dose optimisation may be
possible while maintaining good image contrast. The
change in the ratio of activity in whole blood to
plasma suggests that immediately following injection,
[18F]AH113804 is primarily distributed in plasma, but
slowly accumulates in red blood cells as time
progresses.
The mean NCA for the gallbladder in the female
subjects was 75% less than in the males while kidney
and bladder NCA were, respectively, 90 and 10%
greater. The NCA to the heart wall was 183% greater
for the females than the males. However, uptake in
the gallbladder is relatively low and there is no differ-
ence in gallbladder absorbed dose between sexes. The
difference in heart wall NCA may be attributed to er-
rors in its estimation and the small sample size. The
difference in NCA in the kidney and bladder does
impact on the effective dose calculation as discussed
below.
Internal radiation dosimetry
The mean effective dose was more than 40% higher in
female than male subjects, predominantly originating







Male subjects Female subjects
Mean Minimum Maximum Mean Minimum Maximum
Adrenal glands 1.00E−02 9.39E−03 1.05E−02 1.28E−02 1.16E−02 1.40E−02
Brain 3.11E−03 2.80E−03 3.35E−03 3.25E−03 3.07E−03 3.42E−03
Breasts 6.05E−03 5.70E−03 6.52E−03 7.03E−03 6.76E−03 7.29E−03
Gallbladder wall 1.42E−02 1.29E−02 1.55E−02 1.33E−02 1.25E−02 1.41E−02
Gastrointestinal
tract walls
Lower large intestine 1.55E−02 1.44E−02 1.66E−02 2.02E−02 2.02E−02 2.02E−02
Small intestine 1.20E−02 1.11E−02 1.34E−02 1.41E−02 1.47E−02 1.44E−02
Stomach wall 8.79E−03 8.26E−03 9.33E−03 1.10E−02 9.81E−03 1.04E−02
Upper large intestine 1.13E−02 1.04E−02 1.26E−02 1.38E−02 1.43E−02 1.41E−02
Heart wall 1.45E−02 1.22E−02 1.56E−02 2.25E−02 2.16E−02 2.34E−02
Kidneys 3.58E−02 3.01E−02 4.14E−02 6.86E−02 4.68E−02 9.03E−02
Liver 2.02E−02 1.71E−02 2.51E−02 2.39E−02 2.22E−02 2.55E−02
Lungs 1.39E−02 1.31E−02 1.49E−02 1.51E−02 1.40E−02 1.62E−02
Muscle 8.74E−03 8.37E−03 9.16E−03 1.05E−02 1.01E−02 1.08E−02
Ovaries 1.50E−02 1.42E−02 1.58E−02 1.97E−02 1.95E−02 1.99E−02
Pancreas 1.03E−02 9.71E−03 1.08E−02 1.24E−02 1.15E−02 1.33E−02
Red marrow 7.98E−03 7.59E−03 8.42E−03 9.61E−03 9.21E−03 1.00E−02
Osteogenic cells 1.11E−02 1.04E−02 1.19E−02 1.34E−02 1.28E−02 1.40E−02
Skin 5.95E−03 5.62E−03 6.34E−03 6.90E−03 6.62E−03 7.17E−03
Spleen 2.24E−02 1.94E−02 2.55E−02 2.56E−02 2.36E−02 2.76E−02
Testes 1.15E−02 1.10E−02 1.19E−02 – – –
Thymus gland 7.63E−03 7.22E−03 8.23E−03 8.85E−03 8.55E−03 9.15E−03
Thyroid gland 8.78E−03 6.50E−03 1.27E−02 1.04E−02 8.66E−03 1.21E−02
Urinary bladder wall 2.74E−01 2.43E−01 3.09E−01 4.28E−01 4.16E−01 4.40E−01
Uterus 2.47E−02 2.28E−02 2.67E−02 3.08E−02 3.06E−02 3.09E−02
Total body 9.25E−03 8.87E−03 9.65E−03 1.13E−02 1.08E−02 1.17E−02
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from the almost 60% higher absorbed dose to the urin-
ary bladder wall and more than 90% higher absorbed
dose to the kidneys in females. The high kidney
absorbed dose to subject 2 (0.090 mGy/MBq) could be
attributed to the retention of urine in the kidney as pre-
viously described but the kidney absorbed dose for sub-
ject 6 (0.047 mGy/MBq) is also greater than for any of
the male subjects (mean 0.036 mGy/MBq) and the dif-
ference in effective dose between male and female sub-
jects remains notable.
Gender-specific differences in effective dose occur
in, for example, 18F-choline (0.027 mSv/MBq in males
versus 0.037 mSv/MBq in females) and 18F-FLT
(0.028 mSv/MBq in males versus 0.033 mSv/MBq in
females) [18], but results are inevitably confounded by
the small sample size. To place the calculated sex-
averaged effective dose of 0.03 mSv/MBq in a clinical
context, the effective dose for the most commonly
used 18F-labelled PET tracer, FDG, is approximately
0.019 mSv/MBq [19].
Conclusions
AH113804 (18F) Injection is a safe and well-tolerated
PET radiopharmaceutical with a radiation dosimetry
profile favourable for clinical PET imaging. Excretion of
18F was rapid and the highest absorbed doses were re-
ceived by the urinary bladder wall, the kidneys and the
uterus. The mean effective dose, 0.03 mSv/MBq, is
slightly greater than for other common 18F PET imaging
radiopharmaceuticals, but due to the dominant urinary
excretion, future studies should ensure proper hydration
of subjects to promote frequent voiding and minimise
the absorbed radiation dose to the subject.
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